208 related articles for article (PubMed ID: 37463790)
21. Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma.
Zhou P; Chen D; Zhu B; Chen W; Xie Q; Wang Y; Tan Q; Yuan B; Zuo X; Huang C; Zhu H; Li G
Front Immunol; 2020; 11():594212. PubMed ID: 33552051
[TBL] [Abstract][Full Text] [Related]
22. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
23. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
Kim H; Park S; Han KY; Lee N; Kim H; Jung HA; Sun JM; Ahn JS; Ahn MJ; Lee SH; Park WY
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787939
[TBL] [Abstract][Full Text] [Related]
24. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases.
Ying S; Ke H; Ding Y; Liu Y; Tang X; Yang D; Li M; Liu J; Yu B; Xiang J; Mao X; Han-Zhang H; Hu W; Chen L
Cancer Biol Ther; 2019; 20(4):562-570. PubMed ID: 30395779
[TBL] [Abstract][Full Text] [Related]
25. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
26. Infiltration of NK and plasma cells is associated with a distinct immune subset in non-small cell lung cancer.
Backman M; La Fleur L; Kurppa P; Djureinovic D; Elfving H; Brunnström H; Mattsson JSM; Lindberg A; Pontén V; Eltahir M; Mangsbo S; Gulyas M; Isaksson J; Jirström K; Kärre K; Leandersson K; Mezheyeuski A; Pontén F; Strell C; Lindskog C; Botling J; Micke P
J Pathol; 2021 Nov; 255(3):243-256. PubMed ID: 34339045
[TBL] [Abstract][Full Text] [Related]
27. Tumor-infiltrating CD36
Ao YQ; Gao J; Zhang LX; Deng J; Wang S; Lin M; Wang HK; Ding JY; Jiang JH
BMC Cancer; 2023 Apr; 23(1):367. PubMed ID: 37085798
[TBL] [Abstract][Full Text] [Related]
28. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
Front Immunol; 2021; 12():651086. PubMed ID: 34248939
[TBL] [Abstract][Full Text] [Related]
29. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
30. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer.
Fang Y; Wang Y; Zeng D; Zhi S; Shu T; Huang N; Zheng S; Wu J; Liu Y; Huang G; Xue Y; Bin J; Liao Y; Shi M; Liao W
Oncoimmunology; 2021; 10(1):1951019. PubMed ID: 34345533
[TBL] [Abstract][Full Text] [Related]
32. [Effect of FBXW7 gene mutation on the prognosis of immunotherapy in patients with non-small cell lung cancer].
Liu XY; Cui YN; Li J; Zhang Z; Guo RH
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):914-921. PubMed ID: 35385962
[No Abstract] [Full Text] [Related]
33. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
34. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
35. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Morishita Y; Kashiwabara K; Takazawa M; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2017 May; 12(5):791-803. PubMed ID: 28088513
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
[TBL] [Abstract][Full Text] [Related]
37. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Lin A; Zhang H; Meng H; Deng Z; Gu T; Luo P; Zhang J
Front Immunol; 2021; 12():667875. PubMed ID: 34603277
[TBL] [Abstract][Full Text] [Related]
38. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
[TBL] [Abstract][Full Text] [Related]
39. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
40. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]